New Directions in Pulmonary Gene Therapy

Area of Science:

• Pulmonary Medicine
• Gene Therapy
• Genetic Disorders

Background:

• Gene therapy for lung diseases faces challenges in efficient delivery and phenotypic correction.
• While ex vivo therapies have advanced in other organs, in vivo lung therapeutics lag in clinical translation.
• Recent years have seen rapid development in gene addition and editing for monogenic disorders.

Purpose of the Study:

• To review current gene therapy developments for cystic fibrosis, alpha-1 antitrypsin deficiency, and surfactant protein deficiencies.
• To explore various gene addition and gene editing strategies under investigation for lung diseases.
• To discuss the persistent challenges associated with delivering gene therapies to the lung.

Main Methods:

• Literature review of recent advancements in gene therapy for specific monogenic lung disorders.
• Analysis of gene addition and gene editing strategies applicable to lung diseases.
• Identification and discussion of key delivery challenges for pulmonary gene therapeutics.

Main Results:

• Significant progress in gene addition and editing strategies for monogenic lung diseases.
• Identification of specific therapeutic approaches for cystic fibrosis, alpha-1 antitrypsin deficiency, and surfactant protein deficiencies.
• Persistent challenges in achieving efficient and targeted delivery of gene therapies to lung tissues.

Conclusions:

• Gene therapy holds potential for treating monogenic lung disorders, with rapid advancements in strategies.
• Overcoming delivery barriers is crucial for translating these in vivo therapies to clinical practice.
• Continued research into novel delivery systems is essential for the future of pulmonary gene therapy.